Home / Stocks / Nephrocare Health Serv L
NEPHROPLUS

Nephrocare Health Serv L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹641.95

Change

-11.05 (-1.69%)

Open

₹653.0

Prev. Close

₹653.0

Day High

₹656.1

Day Low

₹640.0

Volume Analysis

Traded

60,125

Delivered

28,947

Delivery %

48.14%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (21.0%)

Weaknesses (2)

  • •Low return on equity (8.83%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (31.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹668.14 ₹662.12 ₹652.04 ₹646.02 ₹635.94 ₹629.92 ₹619.84
Fibonacci ₹662.12 ₹655.97 ₹652.17 ₹646.02 ₹639.87 ₹636.07 ₹629.92
Camarilla ₹646.38 ₹644.9 ₹643.43 ₹646.02 ₹640.47 ₹639.0 ₹637.52

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+40.84%

1 Week

+3.1%

1 Month

+5.43%

3 Months

-7.51%

6 Months

+5.67%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹142.61

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.64%

Net margin 11.53% × asset turnover 0.61x × equity multiplier 1.37x

Company Overview

Sector

Healthcare

Market Cap

₹6,500 Cr

P/E (TTM)

50.8

ROE

8.83%

Book Value

₹118.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Nephrocare Health Serv L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Valuation (16/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); low return on equity (8.83%); promoter holding is falling. Strong 3-year revenue growth (31.7%).

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

16

Cash Flow

67

Corporate Governance

43

Momentum

59

Institutional Ownership

55

Business Quality

67

Risk & Volatility

72

Liquidity

24

From Screener.in

  • +Company has reduced debt.
  • +Company has delivered good profit growth of 162% CAGR over last 5 years
  • −Stock is trading at 5.45 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last quarter: -5.53%
  • −Company has a low return on equity of 10.2% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

NRC approved 38,236 ESOPs under ESOP 2026 at ₹513.60 each on November 17, 2026.

The Company has approved allotment of 3,42,130 equity shares of Rs. 2/- each, pursuant to the exercise of stock ....

Transcripts for the Investors Earnings call held on November 4, 2026.

The Company has scheduled an investor conference call as per the disclosure annexed herewith.

Uploaded audio recording of Q2FY27 investor conference call held on November 4, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 197 219 228 246 260 266 282 303
Expenses + 153 168 180 182 199 215 221 240
Operating Profit 44 51 48 64 61 51 60 63
OPM % 22.0% 23.0% 21.0% 26.0% 23.0% 19.0% 21.0% 21.0%
Other Income + 5 4 7 4 3 12 7 8
Interest 5 6 6 45 6 3 2 3
Depreciation 18 19 20 23 22 26 25 28
Profit before tax 26 30 29 -1 36 33 41 40
Tax % 24.0% 17.0% 17.0% 1,427.0% 11.0% 9.0% 22.0% 17.0%
Net Profit + 20 25 24 -9 32 30 32 34
EPS in Rs 2 3 3 -1 3 3 3 3
Raw PDF — — — — — — — —
YoY Sales growth — — — — 32 21 24 23

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 286 318 437 566 756 999 1,110
Expenses + 248 302 389 465 589 774 875
Operating Profit 37 16 49 101 167 225 235
OPM % 13.0% 5.0% 11.0% 18.0% 22.0% 23.0% 21.0%
Other Income + 5 10 6 8 14 23 30
Interest 7 10 16 20 21 60 14
Depreciation 34 42 47 56 72 91 100
Profit before tax 1 -27 -9 33 87 97 151
Tax % 31.0% -21.0% 37.0% -6.0% 23.0% 21.0% —
Net Profit + 1 -21 -12 35 67 77 128
EPS in Rs 0 -2 -1 4 7 8 13
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — 11 38 29 34 32 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 245 391 384 409 579 1,096 1,169
Borrowings + 140 119 200 271 261 80 149
Other Liabilities + 42 59 81 124 153 271 295
Total Liabilities 428 571 666 806 994 1,467 1,633
Fixed Assets + 192 205 239 356 396 517 634
CWIP 2 43 34 1 6 6 7
Investments 0 0 0 0 51 178 214
Other Assets + 234 322 393 449 542 767 778
Total Assets 428 571 666 806 994 1,467 1,633
Equity Capital 2 2 2 2 2 20 20

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 32 14 11 72 135 233
Cash from Investing Activity + -62 -130 -76 -52 -125 -392
Cash from Financing Activity + 36 121 60 27 54 157
Net Cash Flow 5 6 -4 47 65 -2
Free Cash Flow -29 -64 -62 -8 35 113
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 49 119 14 80 82 116

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 63.85% → 58.32%
  Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 18.74% 17.56% 18.3% 21.85%
Promoters 63.85% 63.85% 63.85% 58.32%
FII 9.3% 9.94% 8.78% 11.73%
DII 8.1% 8.64% 9.05% 8.11%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Nephrocare Health Serv L (this stock) 6,500 50.8 5.46 8.83%
Sun Pharma Adv.res.co.ltd 6,680 4.05 4.64 279.0%
Fdc Limited 6,177 18.8 2.31 11.5%
Innova Captab Limited 5,938 35.6 5.09 13.7%
Bliss Gvs Pharma Ltd 7,075 43.5 5.5 11.8%
Kovai Medical Center & Ho 7,108 123.0 24.58 22.2%
Sanofi India Limited 7,375 16.7 8.56 47.1%

Which Mutual Funds Hold Nephrocare Health Serv L?

Frequently Asked Questions about Nephrocare Health Serv L

Community Sentiment

What are other investors saying about Nephrocare Health Serv L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.